Efficacy and Safety of Pioglitazone Plus Phototherapy Versus Phototherapy in Patients With Plaque Type Psoriasis: A Double Blinded Randomized Controlled Trial Publisher Pubmed



Ghiasi M¹ ; Ebrahimi S¹ ; Lajevardi V¹ ; Taraz M² ; Azizpour A¹ Show Affiliations
Source: Journal of Dermatological Treatment Published:2019

Abstract

Introduction: Thiazolidinediones have shown a good therapeutic effect in psoriasis treatment with no major adverse effects. The purpose of this study was to evaluate and compare the therapeutic effects of the combination of phototherapy and Pioglitazone with the phototherapy alone on plaque psoriasis patients. Methods and Materials: About 60 adults with plaque type psoriasis entered the study. They were randomly divided into two groups; one with pioglitazone and one with placebo and both underwent 30 sessions of phototherapy during 10 weeks. Before and after the treatment Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) were assessed. Side effects of the treatment were also investigated. Results: The average PASI of the pioglitazone group was reduced from 20.9 ± 9.8 to 1.8 ± 1.4 (p <.001) versus the placebo group in which the PASI was reduced from 22 ± 8.5 to 4.4 ± 4. In other words, PASI was reduced in the pioglitazone and placebo group by 83.5% and 56.7% respectively (p <.05). The two groups didn’t have a significant difference in reducing the DLQI (p =.315). Conclusion: Pioglitazone can vastly enhance the effectiveness of phototherapy in plaque psoriasis patients without causing any important adverse effect and with no success in improving the score of DLQI. © 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group.